Welcome to our dedicated page for Fennec Pharmaceuticals news (Ticker: FENC), a resource for investors and traders seeking the latest updates and insights on Fennec Pharmaceuticals stock.
Fennec Pharmaceuticals Inc. reports developments as a commercial-stage specialty pharmaceutical company focused on PEDMARK® (sodium thiosulfate injection), a therapy used to reduce the risk of cisplatin-induced ototoxicity in pediatric patients with localized, non-metastatic solid tumors. The company also markets the product in Europe and the United Kingdom under the PEDMARQSI® name and has disclosed a licensing arrangement for commercialization in additional non-U.S. markets.
Recurring news themes include PEDMARK product sales and financial results, commercialization updates, scientific abstracts, investigator-sponsored and real-world studies in cancer patients receiving cisplatin-based chemotherapy, product exclusivity and patent matters, and equity compensation actions under Nasdaq rules.
Fennec Pharmaceuticals (NASDAQ:FENC) reported strong second quarter 2026 results, driven by continued commercial uptake of PEDMARK. Net product sales rose to $17.1 million, up from $9.7 million a year earlier, and total revenue reached $17.9 million. Non-GAAP adjusted EBITDA improved to $2.8 million from a loss of $1.2 million, with net income of $2.0 million versus a prior-year net loss of $3.2 million.
Selling and marketing expenses increased to $10.7 million as the company expanded its commercial organization, while G&A fell to $4.6 million. Cash and cash equivalents were $41.2 million at June 30, 2026. New real-world and investigator-sponsored data for PEDMARK were presented at ASCO 2026, and management reiterated expectations that current cash plus projected PEDMARK revenues will fund the business under its current operating plan.
Fennec Pharmaceuticals (NASDAQ: FENC; TSX: FRX) will release its second quarter 2026 financial results before U.S. market open on Tuesday, August 11, 2026, followed by a management conference call and webcast at 8:30 a.m. Eastern Time.
Investors can access the live webcast via Fennec’s website under Investors & Media > News & Events/Event Calendar, or through the provided webcast and participant registration links. A replay will be archived on the company’s site for 30 days. Fennec is a commercial-stage specialty pharmaceutical company focused on PEDMARK/PEDMARQSI, approved in the U.S., EU and U.K. to reduce the risk of platinum-induced ototoxicity in cancer patients, with an exclusive commercialization agreement with Norgine in Europe, the U.K., Australia and New Zealand and patent protection to 2039.
Fennec Pharmaceuticals (NASDAQ:FENC) granted inducement incentive stock options to one new non-executive employee under its 2026 Equity Inducement Plan. The award covers 15,000 common shares at an exercise price of $9.06 per share, with a ten-year term and time-based vesting.
Fennec Pharmaceuticals (NASDAQ:FENC) approved an inducement grant of 10,000 incentive stock options for a new non-executive employee under its 2026 Equity Inducement Plan, effective June 15, 2026.
The options have a $9.00 exercise price, a 10-year term, and three-year, time-based vesting in line with Nasdaq Listing Rule 5635(c)(4).
Fennec (NASDAQ:FENC)/b) reported voting results from its Annual General and Special Meeting held June 10, 2025. Shareholders elected five director nominees, each receiving at least 93.62% of votes cast. Investors also approved auditor appointment, executive compensation and amendments to the 2020 Equity Incentive Plan with strong majorities.
Fennec Pharmaceuticals (NASDAQ:FENC) announced new independent research on PEDMARK at the 2026 ASCO Annual Meeting. Four studies span pediatric, adolescent, young adult, and adult cancer patients.
Data include a Japanese Phase 2/3 trial showing reduced cisplatin-induced hearing loss and real-world studies supporting feasible, ≥6-hour delayed dosing without compromising cisplatin’s antitumor activity.
Fennec Pharmaceuticals (NASDAQ:FENC) granted stock options under Nasdaq Listing Rule 5635(c)(4) as inducement awards to three new non-executive employees. On May 11, 2026, the board’s Compensation Committee approved options for an aggregate 50,000 common shares under the 2026 Equity Inducement Plan.
The options have a $9.75 exercise price, a 10-year term, and vest over three years, with one-third vesting after one year and the remainder vesting monthly over 24 months, subject to continued employment.
Fennec Pharmaceuticals (NASDAQ:FENC) reported Q1 2026 net revenues of $15.1 million, a 73% year-over-year increase, driven by broader PEDMARK sales, including new AYA accounts. Net income was $0.2 million (EPS $0.01) versus a $1.2 million loss in Q1 2025. Cash and equivalents rose to $40.1 million.
Selling and marketing expenses increased to $11.4 million while G&A declined to $3.2 million. Fennec initiated a third institution-led PEDMARK study in AYA and adult head and neck and testicular cancers, and four PEDMARK abstracts will appear at the 2026 ASCO Annual Meeting.
Fennec Pharmaceuticals (NASDAQ: FENC) will release Q1 2026 financial results before U.S. market open on Thursday, May 14, 2026. Management will host a conference call and live webcast at 8:30 a.m. ET. A replay will be archived on the company website for 30 days.
Fennec Pharmaceuticals (NASDAQ: FENC) announced four abstracts evaluating PEDMARK® (sodium thiosulfate) were accepted to the 2026 ASCO Annual Meeting, May 29–June 2, 2026, in Chicago. Two items are poster presentations and two are abstract-only publications.
PEDMARK is approved for pediatric patients one month and older and carries a NCCN 2A recommendation for adolescent and young adult patients. Full abstracts will be available on the ASCO website on May 21, 2026 at 5:00 p.m. ET.